Celanese Corp
CE
43.86
-0.99
-2.21%
Celanese Corp
US · CE
#2141 by market cap
Listed 1970
43.86
-0.99
-2.21%
Live - 5344 symbols - heartbeat 329s ago
· 2026-10-08 06:05
Pre-market
44.36
+1.14%
After-hours
43.15
-1.62%
- Market cap
- 4.81B
- P/E (TTM)i
- -4.11
- P/Bi
- 1.16
- EPSi
- -10.64
- Div yieldi
- 0.27%
- 52W posi
- 25%
Reader sentiment
Are you bullish or bearish on CE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.47, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -7.05% YoY
Margins
- Gross margin
- 20.45%
- Operating margin
- 8.01%
- Net margin
- -12.21%
Key ratios & quality
- Enterprise valuei
- 16.22B
- Altman Z-Scorei
- 1.47
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.16B | 6.30B | 5.66B | 8.54B | 9.67B | 10.93B | 10.27B | 9.54B |
| Gross profit | 1.97B | 1.61B | 1.29B | 2.68B | 2.38B | 2.58B | 2.34B | 1.95B |
| Selling & admin expenses | 546.00M | 483.00M | 482.00M | 633.00M | 824.00M | 1.08B | 1.03B | 899.00M |
| Research & development | 72.00M | 67.00M | 74.00M | 86.00M | 112.00M | 146.00M | 130.00M | 125.00M |
| Operating profit | 1.33B | 1.03B | 715.00M | 1.94B | 1.38B | 1.20B | 1.01B | 764.00M |
| Pretax profit | 1.51B | 988.00M | 2.25B | 2.25B | 1.42B | 1.16B | -1.02B | -1.22B |
| Tax | 292.00M | 124.00M | 247.00M | 330.00M | -489.00M | -795.00M | 507.00M | -90.00M |
| Net profit | 1.21B | 858.00M | 1.99B | 1.90B | 1.90B | 1.95B | -1.53B | -1.15B |
| Basic EPS | 9 | 7 | 17 | 17 | 17 | 18 | -14 | -11 |
| Diluted EPS | 8.91 | 6.84 | 16.75 | 16.86 | 17.34 | 17.76 | -14.11 | -10.64 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.39B | 2.53B | 2.42B | 2.20B | 2.34B | 2.75B |
| Gross profit | 474.00M | 534.00M | 521.00M | 423.00M | 468.00M | 618.00M |
| Selling & admin expenses | 231.00M | 214.00M | 231.00M | 223.00M | 226.00M | 251.00M |
| Research & development | 31.00M | 31.00M | 31.00M | 32.00M | 28.00M | 29.00M |
| Operating profit | 172.00M | 247.00M | 217.00M | 128.00M | 174.00M | 299.00M |
| Pretax profit | -6.00M | 133.00M | -1.36B | 13.00M | 82.00M | 142.00M |
| Tax | 9.00M | -77.00M | -7.00M | -15.00M | 33.00M | 11.00M |
| Net profit | -20.00M | 200.00M | -1.35B | 22.00M | 48.00M | 129.00M |
| Basic EPS | 0 | 2 | -12 | 0 | 0 | 1 |
| Diluted EPS | -0.22 | 1.80 | -12.39 | 0.17 | 0.40 | 1.13 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.87B | 2.77B | 3.76B | 3.81B | 6.61B | 6.22B | 5.13B | 5.69B |
| Cash & ST investments | 470.00M | 503.00M | 1.49B | 536.00M | 1.51B | 1.81B | 962.00M | 1.26B |
| Inventory | 1.05B | 1.04B | 978.00M | 1.52B | 2.81B | 2.36B | 2.28B | 2.22B |
| Total assets | 9.31B | 9.48B | 10.91B | 11.98B | 26.27B | 26.60B | 22.84B | 21.70B |
| Total current liabilities | 1.78B | 1.75B | 1.97B | 2.51B | 4.07B | 4.07B | 3.89B | 3.68B |
| Short-term debt | 561.00M | 525.00M | 532.00M | 828.00M | 1.39B | 1.47B | 1.58B | 1.28B |
| Long-term debt | 2.97B | 3.41B | 3.23B | 3.18B | 13.37B | 12.30B | 11.08B | 11.39B |
| Total liabilities | 5,934,000,000.00 | 6,578,000,000.00 | 7,014,000,000.00 | 7,438,000,000.00 | 20,167,000,000.00 | 19,045,000,000.00 | 17,275,000,000.00 | 17,223,000,000.00 |
| Total equity | 3.38B | 2.90B | 3.90B | 4.54B | 6.11B | 7.55B | 5.56B | 4.47B |
| Retained earnings | 5.85B | 6.40B | 8.09B | 9.68B | 11.27B | 12.93B | 11.05B | 9.88B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.42B | 5.68B | 6.09B | 5.69B | 5.97B | 5.80B |
| Cash & ST investments | 951.00M | 1.17B | 1.44B | 1.26B | 1.76B | 1.36B |
| Inventory | 2.31B | 2.29B | 2.21B | 2.22B | 2.28B | 2.31B |
| Total assets | 23.20B | 23.71B | 22.17B | 21.70B | 21.74B | 21.41B |
| Total current liabilities | 2.80B | 2.77B | 3.73B | 3.68B | 4.32B | 4.01B |
| Short-term debt | 484.00M | 330.00M | 1.27B | 1.28B | 1.82B | 1.38B |
| Long-term debt | 12.38B | 12.69B | 11.66B | 11.39B | 10.81B | 10.70B |
| Total liabilities | 17,582,000,000.00 | 18,009,000,000.00 | 17,790,000,000.00 | 17,223,000,000.00 | 17,250,000,000.00 | 16,820,000,000.00 |
| Total equity | 5.62B | 5.70B | 4.38B | 4.47B | 4.49B | 4.59B |
| Retained earnings | 11.08B | 11.24B | 9.86B | 9.88B | 9.92B | 10.04B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.56B | 1.45B | 1.34B | 1.76B | 1.82B | 1.90B | 966.00M | 1.15B |
| Depreciation & amortization | 349.00M | 356.00M | 356.00M | 378.00M | 478.00M | 739.00M | 823.00M | 786.00M |
| Free cash flow | 1.22B | 1.08B | 979.00M | 1.29B | 1.28B | 1.33B | 531.00M | 803.00M |
| Dividends paid | -280.00M | -300.00M | -293.00M | -304.00M | -297.00M | -305.00M | -307.00M | -13.00M |
| Stock buybacks / issuance | -805.00M | -996.00M | -650.00M | -1.00B | -17.00M | -- | -- | -- |
| Ending cash balance | 439.00M | 463.00M | 955.00M | 536.00M | 1.51B | 1.81B | 962.00M | 1.26B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 37.00M | 410.00M | 447.00M | 252.00M | 76.00M | 209.00M |
| Depreciation & amortization | 191.00M | 193.00M | 201.00M | 201.00M | 208.00M | 249.00M |
| Free cash flow | -65.00M | 317.00M | 383.00M | 168.00M | 10.00M | 147.00M |
| Dividends paid | -3.00M | -3.00M | -3.00M | -4.00M | -3.00M | -3.00M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 951.00M | 1.17B | 1.44B | 1.26B | 1.76B | 1.36B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 41.12 | 31.03 | 65.80 | 49.00 | 38.55 | 30.80 | -24.82 | -25.26 |
| ROA %i | 12.81 | 9.07 | 19.48 | 16.52 | 9.90 | 7.41 | -6.16 | -5.23 |
| ROIC %i | 19.99 | 14.41 | 29.43 | 24.68 | 14.81 | 11.91 | -5.16 | -3.07 |
| 5-year avg ROE %i | 28.50 | 30.18 | 41.00 | 43.55 | 45.10 | 42.98 | 31.73 | 13.49 |
| EBIT margin %i | 22.85 | 17.52 | 41.73 | 27.40 | 18.88 | 17.39 | -3.11 | -5.44 |
| FCF / sales %i | 17.07 | 17.21 | 17.31 | 15.11 | 13.19 | 12.17 | 5.17 | 8.41 |
| Current ratioi | 1.62 | 1.58 | 1.91 | 1.52 | 1.63 | 1.53 | 1.32 | 1.55 |
| Quick ratioi | 1.01 | 0.96 | 1.38 | 0.88 | 0.88 | 0.88 | 0.66 | 0.74 |
| Debt / assetsi | 37.91 | 43.43 | 36.36 | 35.11 | 57.57 | 53.01 | 56.71 | 59.62 |
| LT debt / equityi | 99.53 | 143.20 | 97.42 | 80.59 | 243.69 | 178.06 | 221.72 | 287.95 |
| Interest coveragei | 13.08 | 9.59 | 21.65 | 25.70 | 4.51 | 2.64 | -0.47 | -0.74 |
| Revenue CAGR (3Y) %i | 8.04 | 5.33 | -2.71 | 6.06 | 15.38 | 24.55 | 6.35 | -0.45 |
| Net income CAGR (3Y) %i | 58.35 | -1.81 | 33.04 | 16.12 | 30.51 | -0.71 | -- | -- |
| FCF CAGR (3Y) %i | 52.84 | 18.77 | 22.24 | 1.85 | 5.59 | 10.78 | -25.61 | -14.31 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -27.15 | -26.04 | -55.02 | -25.26 | -23.72 | -24.76 |
| ROA %i | -6.76 | -6.54 | -12.85 | -5.23 | -4.88 | -5.18 |
| ROIC %i | -5.85 | -5.62 | -13.57 | -3.07 | -2.56 | -4.29 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.76 | -5.27 | -21.16 | -5.44 | -4.40 | -4.12 |
| FCF / sales %i | 4.99 | 6.36 | 10.55 | 8.41 | 9.25 | 7.29 |
| Current ratioi | 1.94 | 2.05 | 1.63 | 1.55 | 1.38 | 1.45 |
| Quick ratioi | 1.01 | 1.12 | 0.84 | 0.74 | 0.80 | 0.81 |
| Debt / assetsi | 56.67 | 56.15 | 59.56 | 59.62 | 59.37 | 57.91 |
| LT debt / equityi | 244.16 | 246.10 | 301.80 | 287.95 | 272.90 | 264.29 |
| Interest coveragei | -0.71 | -0.77 | -2.99 | -0.74 | -0.59 | -0.55 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Engineered materials is the largest reported line at 52.54% of revenue, across 3 reported segments.
- Acetyl Chain follows at 48.29%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Engineered materials52.54%
Acetyl Chain48.29%
Quote time 2026-10-08 06:05:55 · For reference only, not investment advice and not tailored to your situation.